Recent Research into the Bladder Cancer - Pipeline Review, H1 2017

Bladder Cancer - Pipeline Review, H1 2017 is a new market research publication announced by Reportstack. This report provides an overview of the Bladder Cancer (Oncology) pipeline landscape.

Bladder cancer occurs in tissues of the urinary bladder. Symptoms include blood or blood clots in the urine, frequent urination, lower back pain on one side of the body and burning during urination. Risk factors for bladder cancer include smoking, exposure to substances such as rubber, certain dyes and textiles, paint, and hairdressing supplies, diet rich in fried meats and fat, old age, sex and color, certain parasitic infections. Treatment of bladder cancer includes chemotherapy, surgery, biological therapy and radiation therapy.

Complete report available @ Bladder Cancer - Pipeline Review, H1 2017

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Bladder Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Bladder Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bladder Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Bladder Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 9, 51, 43, 1, 52 and 14 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 4, 2, 11 and 2 molecules, respectively.

Bladder Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Bladder Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Bladder Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Bladder Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Bladder Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Bladder Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Bladder Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Bladder Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned

4SC AG Adaptimmune Therapeutics Plc ADC Therapeutics Sarl Agenus Inc Altor BioScience Corp AndroScience Corp ANP Technologies Inc APIM Therapeutics AS Archivel Farma SL Argos Therapeutics Inc Arno Therapeutics Inc Array BioPharma Inc Asana BioSciences LLC Asieris Pharmaceuticals Co Ltd Astellas Pharma Inc Astex Pharmaceuticals Inc AstraZeneca Plc AVEO Pharmaceuticals Inc Bavarian Nordic A/S Bayer AG BioCancell Ltd Biomics Biotechnologies Co Ltd Bioncotech Therapeutics SL Biotest AG Boehringer Ingelheim GmbH Bristol-Myers Squibb Company Celgene Corp Cellceutix Corp Celldex Therapeutics Inc Celprogen Inc Celsion Corp Celyad SA Cold Genesys Inc Corvus Pharmaceuticals Inc CytomX Therapeutics Inc Cytori Therapeutics Inc Eisai Co Ltd Eleven Biotherapeutics Inc Eli Lilly and Company Elsalys Biotech SAS EpiThany Inc Esperance Pharmaceuticals Inc Exelixis Inc Exicure Inc F. Hoffmann-La Roche Ltd Five Prime Therapeutics Inc For-Robin Inc Gene Signal International SA Genmab A/S GlaxoSmithKline Plc H3 Biomedicine Inc Hamlet Pharma AB Hanmi Pharmaceuticals Co Ltd HitGen LTD Horizon Pharma Plc Idera Pharmaceuticals Inc Immunocore Ltd Immunomedics Inc Immupharma Plc Incanthera Ltd Incyte Corp InteRNA Technologies BV Johnson & Johnson Laboratoires Pierre Fabre SA Lion Biotechnologies Inc LipoMedix Pharmaceutical Inc MacroGenics Inc Marina Biotech Inc MaxiVAX SA Meabco A/S Medicenna Therapeutics Corp MedImmune LLC Merck & Co Inc Merck KGaA Mirati Therapeutics Inc Moleculin Biotech Inc MTG Biotherapeutics Inc NanoCarrier Co Ltd Nektar Therapeutics Omeros Corp Oncogenex Pharmaceuticals Inc OncoTherapy Science Inc Oncovir Inc Optimum Therapeutics LLC Pfizer Inc Pharma Mar SA Philogen SpA Plexxikon Inc Polaris Pharmaceuticals Inc Provecs Medical GmbH Provectus Biopharmaceuticals Inc PsiOxus Therapeutics Ltd Rexahn Pharmaceuticals Inc Samyang Biopharmaceuticals Corp Sanofi Sareum Holdings Plc Shionogi & Co Ltd Sierra Oncology Inc Sillajen Biotherapeutics Sorrento Therapeutics Inc Spectrum Pharmaceuticals Inc Stemline Therapeutics Inc Sun Pharma Advanced Research Company Ltd Taiwan Liposome Company Ltd Taris Biomedical LLC Theralase Technologies Inc Theravectys SA Tolero Pharmaceuticals Inc Transgene SA UroGen Pharmaceuticals Ltd Vakzine Projekt Management GmbH Vault Pharma Inc Vaxeal Holding SA Vaxiion Therapeutics Inc Viralytics Ltd

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

ReportstackMarket Research

###